Guoqiang Wang

Guoqiang Wang

Auto-generated profile, based on publicly available information

Guoqiang Wang

Department of Oncology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Biology Open
Verified
Journal Article
Open access
PDF file
GWGuoqiang Wang
Guoqiang Wang
QYQiongzhi Yang
Qiongzhi Yang
MLMaoyu Li
Maoyu Li
YZYe Zhang
Ye Zhang
YCYu-Xiang Cai
Yu-Xiang Cai
ZCZhuchu Chen
Zhuchu Chen
To investigate the global proteomic profiles of vascular endothelial cells (VECs) in the tumor microenvironment and antiangiogenic therapy for colorectal cancer (CRC), matched pairs of normal (NVECs) and tumor-associated VECs (TVECs) were purified from CRC tissues by laser capture microdissection and subjected to iTRAQ based quantitative proteomics analysis. Here, 216 differentially expressed proteins (DEPs) were identified and performed bioinformatics analysis. Interestingly, these proteins were implicated in epithelial mesenchymal transition (EMT), ECM-receptor interaction, focal adhesion, PI3K-Akt signaling pathway, angiogenesis and HIF-1 signaling pathway, which may play important roles in CRC angiogenesis. Among these DEPs, we found that Tenascin-C (TNC) was upregulated in TVECs of CRC and correlated with CRC multistage carcinogenesis and metastasis. Furthermore, the reduction of tumor-derived TNC could attenuate human umbilical vein endothelial cell (HUVEC) proliferation, migration and tube formation through ITGB3/FAK/Akt signaling pathway. Based on the present work, we provided a large-scale proteomic profiling of VECs in CRC with quantitative information, a certain number of potential antiangiogenic targets and a novel vision in the angiogenesis bio-mechanism of CRC.

29 November 2024 in Medicine
Verified
Journal Article
Open access
GWGuoqiang Wang
Guoqiang Wang
HXHui Xiao
Hui Xiao
ZLZhipan Liang
Zhipan Liang
YFYuxin Feng
Yuxin Feng
LWLiyu Wang
Liyu Wang
LZLuyao Zhang
Luyao Zhang
The tyrosine kinase ephrin type-A receptor 2 (EPHA2) was remarkably elevated expressed in various tumors and plays a crucial role in cancer tumorigenesis and progression, while pan-cancer analyses are currently lacking. This study was designed to analyze the expression status and prognostic significance of EPHA2 in pan-cancer. By mining The Cancer Genome Atlas data, we performed a comprehensive and systematic characterization of EPHA2 across >10,000 samples of 33 types of cancer. EPHA2 expressions were substantially different in most of the normal control and tumor tissues, and it was considerably associated with the prognosis of tumor patients. EPHA2 gene modifications in malignant tumors were mainly missense mutations. There was a significant correlation between EPHA2 expression and cancer-associated fibroblasts in most The Cancer Genome Atlas cancers. Furthermore, functional enrichment analysis showed that the biological role of EPHA2 in tumors was mainly involved in some noticeably pro-oncogenic pathways, such as the Ras signaling pathway, PI3K-Akt signaling pathway, ErbB signaling pathway, MAPK signaling pathway, etc. This study provided the first pan-cancer analyses of EPHA2 in various tumors, and EPHA2 was potentially involved in many cancer types and can be developed as candidates for cancer diagnosis, prognosis, and therapeutic biomarkers. In addition, EPHA2 seemed to be a key modulator of the tumor immune microenvironment and might be a potential biomarker in predicting the immunotherapeutic efficacy for cancer patients.

14 April 2023 in Cancer Research
Verified
Journal Article
Closed access
IEInes Pulido Endrino
Ines Pulido Endrino
QLQiyue Luan
Qiyue Luan
JGJennifer Graeber
Jennifer Graeber
BBBrianna Borger
Brianna Borger
CYChenghao Ying
Chenghao Ying
TSTakeshi Shimamura
Takeshi Shimamura
KRAS is the most frequently mutated oncogene in cancer and is particularly common in lung, pancreatic and colorectal cancers. While KRAS has been undruggable, covalent KRAS G12C inhibitors, sotorasib and adagrasib, that bind preferentially to GDP-bound KRAS and prevent exchange for GTP and interaction with downstream effectors, have been approved for use in NSCLC. While these reagents show promising efficacy and are well-tolerated by patients, acquired drug resistance rapidly develops. The drug resistance landscape of G12C inhibitors is complex, with several mechanisms of resistance already described, ranging from reactivation of mutated RAS or other RAS isoforms, acquisition of new KRAS mutations, and genetic alterations of pro-growth signaling pathways. Thus, an ideal approach to overcoming drug resistance will need to target multiple different mechanisms. We exposed NSCLC and pancreatic cell lines (NCI-H358, NCI-H1373 and MIA PaCa-2, respectively) to increasing doses of sotorasib or adagrasib until the resulting cells grow normally in the presence of 10 µM of each inhibitor. Sotorasib-resistant cells, designated as S-R, remarkably remain sensitive to adagrasib, suggesting that the resistant cells continue to be dependent on mutant KRAS for survival. In contrast, adagrasib-resistant cells, designated as A-R, are resistant to both inhibitors. Treatment of innate and acquired adagrasib-resistant cells with 500 nM adagrasib attenuated RAS activity; however, this is compensated for by increased KRAS, HRAS and NRAS mRNA and restored p-ERK levels, a surrogate marker of RAS activity. Moreover, analysis of RTK activation in drug-resistant cells reveals that adagrasib treatment induces the activity of specific RTKs in a cell-line specific manner. Interestingly, during the acquisition of adagrasib resistance, several RTKs are strongly induced to escape drug inhibition. These results indicate the need to simultaneously reduce both KRAS G12C and compensating RTK activity to effectively treat KRAS G12C NSCLC. The majority of oncogenic RTKs are known to be dependent on the molecular chaperone HSP90 for their proper folding and stability. Therefore, a heterobifunctional chaperone-mediated protein degrader (CHAMP), RNK07421, was designed to specifically target both KRAS G12C and HSP90. RNK07421 induces an artificial ternary complex with KRAS G12C and HSP90, while also inhibiting the activity of both proteins and promoting proteasomal degradation of KRAS G12C via HSP90-associated E3-ligases. Treatment of adagrasib-resistant NSCLC cells and PDOs with RNK07421 resulted in decreased levels of KRAS G12C, p-ERK and RTKs. Furthermore, in vivo treatment with RNK07421 demonstrated dramatic tumor growth inhibition as compared to adagrasib treatment alone. Together, these observations indicate that the novel mechanisms of action of RNK07421 may provide several advantages over G12C inhibitors and possibly other targeted protein degradation agents to effectively treat KRAS G12C-dependent NSCLC. Citation Format: Ines Pulido Endrino, Qiyue Luan, Jennifer Graeber, Brianna Borger, Chenghao Ying, Jinhua Li, Zimo Yang, Zhiyong Wang, Yaya Wang, Yuetong Sun, Yan Dai, Ian Papautsky, Thomas L. Prince, Guoqiang Wang, Kevin P. Foley, Weiwen Ying, Takeshi Shimamura. Overcoming KRAS G12C inhibitor resistance with a chaperone-mediated protein degrader (CHAMP) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr LB231.